Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Unigene Announces Strong Increase in Revenue and Improved Quarterly Income for First Quarter 2007
8:00a ET May 11, 2007 (Business Wire)
Unigene Laboratories, Inc. (OTCBB: UGNE) reports its financial results for the quarter ended March 31, 2007.
Revenue for the three months ended March 31, 2007 increased to $6,328,000 compared to $387,000 for the three months ended March 31, 2006. Revenue from Fortical sales and royalties were $4,461,000 for the three months ended March 31, 2007.
Fortical royalties for the three months ended March 31, 2007 increased to $1,845,000 from $198,000 for the three months ended March 31, 2006. First quarter 2007 Fortical royalties include Upsher-Smith sales for the four month period of December 2006 through March 2007. Fortical sales were $2,616,000 for the three months ended March 31, 2007. Sales to Novartis under our supply agreement were $1,408,000 for the three months ended March 31, 2007. There were no product sales for the three months ended March 31, 2006.
Operating income for the three months ended March 31, 2007 increased to $124,000 from an operating loss of $2,856,000 for the three months ended March 31, 2006.
Unigene's net loss for the three months ended March 31, 2007 was $244,000, or $.00 per share, compared to a net loss of $3,243,000, or $.04 per share for the three months ended March 31, 2006.
The three months ended March 31, 2007 and 2006 includes $393,000 and $165,000, respectively, in expenses for non-cash stock option compensation. As of March 31, 2007, Unigene had approximately $697,000 in expenses for non-cash stock option compensation that remains to be recognized, primarily over the next 12 months.
Total operating expenses were $6,204,000 for the three months ended March 31, 2007, an increase from $3,243,000 for the three months ended March 31, 2006. The increase was primarily due to cost of goods sold on product sales to Upsher-Smith and Novartis.
Our cash balance at March 31, 2007 was $4,646,000, an increase of approximately $1,288,000 from December 31, 2006. Accounts receivable at March 31, 2007 were $7,345,000, an increase of $6,105,000 from December 31, 2006. This was primarily a result of the $5,500,000 milestone payment from Novartis which was received in April 2007.
Deferred licensing fees increased $6,169,000 from December 31, 2006, primarily due to the $8,000,000 in payments from Novartis which were only partially recognized as revenue in the first three months of 2007.
Following are recent highlights and developments:
-- According to IMS, prescriptions for Fortical(R), the Company's first U.S. product that was launched in August 2005, grew to 91,000 in March 2007, reflecting a 32% increase from February 2007. The same source reported that prescriptions for the first quarter of 2007 increased 46% as compared to the fourth quarter of 2006. The nasal calcitonin market share for Fortical during that same period grew from 29% to 45%.
-- Subsequent to March 31, 2007, the Company repaid $1 million of outstanding debt and has restructured its loan obligations, recasting $15.7 million in debt as eight-year term loans. The new notes have a fixed simple interest rate of 9%, and no payments are required for the first three years of the notes. This restructuring will reduce the Company's aggregate annual interest payments, replaces all notes that have been in default and will strengthen the Company's financial position.
-- The Company has progressed in its efforts to improve its oral delivery technology and is in the process of filing new patent applications to protect these inventions. These improvements should enhance the Company's oral delivery technology in general and the calcitonin and PTH programs in particular.
"We are very pleased to report the continued growth of Fortical prescriptions," commented Dr. Warren Levy, President and CEO of Unigene. "The significant increase in first quarter revenue will help fuel the Company's activities in new programs. In combination with the partial loan repayment and the restructuring of the Company's debt to eliminate all defaults and lower interest expense, we will significantly improve the Company's balance sheet."
UNIGENE LABORATORIES, INC. CONDENSED BALANCE SHEETS March 31, 2007 December 31, 2006 ----------------- ----------------- ASSETS (Unaudited) Current assets: Cash and cash equivalents $ 4,645,627 $ 3,357,351 Accounts receivable 7,345,442 1,240,114 Inventory 4,554,028 5,283,000 Prepaid expenses and other current assets 281,303 303,444 ----------------- ----------------- Total current assets 16,826,400 10,183,909 Property, plant and equipment, net 2,403,297 2,364,141 Investment in joint venture 30,656 30,545 Patents and other intangibles, net 1,483,009 1,438,848 Other assets 111,389 33,879 ----------------- ----------------- Total assets $ 20,854,751 $ 14,051,322 ================= ================= LIABILITIES AND STOCKHOLDERS' DEFICIT -------------------------------- Current liabilities: Accounts payable $ 928,954 $ 884,958 Accrued expenses - other 1,877,721 1,806,707 Current portion - deferred licensing fees 2,162,756 762,752 Notes payable - stockholders 8,095,000 8,105,000 Accrued interest - stockholders 8,467,004 8,081,180 Current portion - capital lease obligations 65,108 70,780 ----------------- ----------------- Total current liabilities 21,596,543 19,711,377 Deferred licensing fees, excluding current portion 12,925,402 8,156,262 Capital lease obligations, excluding current portion 28,202 40,880 Deferred compensation 340,016 330,643 ----------------- ----------------- Total liabilities 34,890,163 28,239,162 ----------------- ----------------- Commitments and contingencies Stockholders' deficit: Common Stock - par value $.01 per share, authorized 135,000,000 shares, issued and outstanding: 87,734,515 shares in 2007 and 87,731,015 shares in 2006 877,345 877,310 Additional paid-in capital 105,136,739 104,740,178 Accumulated deficit (120,049,496) (119,805,328) ----------------- ----------------- Total stockholders' deficit (14,035,412) (14,187,840) ----------------- ----------------- $ 20,854,751 $ 14,051,322 ================= =================
UNIGENE LABORATORIES, INC. CONDENSED STATEMENTS OF OPERATIONS (Unaudited) Three months ended March 31, 2007 2006 ------------ ----------- Revenue: Product sales $ 4,023,732 $ -- Royalties 1,845,442 197,702 Licensing revenue 230,856 189,189 Development fees and other 228,242 -- -------------- ------------- 6,328,272 386,891 -------------- ------------- Operating expenses: Research, development and facility expenses 2,124,135 1,581,106 Cost of goods sold 2,019,651 -- General and administrative 2,060,235 1,661,877 -------------- ------------- 6,204,021 3,242,983 -------------- ------------- Operating income (loss) 124,251 (2,856,092) Other income (expense): Interest income 31,723 27,024 Interest expense-principally to stockholders (400,142) (413,604) -------------- ------------- Loss before income taxes (244,168) (3,242,672) Income tax expense -- -- -------------- ------------- Net loss $ (244,168) $(3,242,672) ============== ============= Loss per share - basic and diluted: Net loss per share $ (0.00) $ (0.04) -------------- ------------- Weighted average number of shares outstanding - basic and diluted 87,731,376 84,084,903 ============== =============
About Unigene
Unigene Laboratories, Inc. is a biopharmaceutical company focusing on the oral and nasal delivery of large-market peptide drugs. Due to the size of the worldwide osteoporosis market, Unigene is targeting its initial efforts on developing calcitonin and PTH-based therapies. Fortical(R), Unigene's nasal calcitonin product for the treatment of postmenopausal osteoporosis, received FDA approval and was launched in August 2005. Unigene has licensed the U.S. rights for Fortical to Upsher-Smith Laboratories, worldwide rights for its oral PTH technology to GlaxoSmithKline and worldwide rights for its calcitonin manufacturing technology to Novartis. The Company is also manufacturing a second peptide for Novartis. Unigene's patented oral delivery technology has successfully delivered, in preclinical and/or clinical trials, various peptides including calcitonin, PTH and insulin. Unigene's patented manufacturing technology is designed to cost-effectively produce peptides in quantities sufficient to support their worldwide commercialization as oral or nasal therapeutics. For more information about Unigene, call (973) 882-0860 or visit www.unigene.com. For information about Fortical, visit www.fortical.com.
Safe Harbor statements under the Private Securities Litigation Reform Act of 1995: This press release contains forward-looking statements regarding us and our business, financial condition, results of operations and prospects. Such forward-looking statements include those which express plans, anticipation, intent, contingency, goals, targets or future development and/or otherwise are not statements of historical fact. We have based these forward-looking statements on our current expectations and projections about future events and they are subject to risks and uncertainties known and unknown which could cause actual results and developments to differ materially from those expressed or implied in such statements. These forward-looking statements include statements about the following: general economic and business conditions, our financial condition, competition, our dependence on other companies to commercialize, manufacture and sell products using our technologies, the ability of our products to gain market acceptance and increase market share, the uncertainty of results of animal and human testing, the risk of product liability and liability for human trials, our dependence on patents and other proprietary rights, dependence on key management officials, the availability and cost of capital, the availability of qualified personnel, changes in, or the failure to comply with, governmental regulations, the failure to obtain regulatory approvals for our products and other risk factors discussed in our Securities and Exchange Commission filings. Words such as "anticipates," "expects," "intends," "plans," "predicts," "believes," "seeks," "estimates," "may," "will," "should," "would," "potential," "continue," and variations of these words (or negatives of these words) or similar expressions, are intended to identify forward-looking statements. In addition, any statements that refer to expectations, projections, or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to certain risks, uncertainties, and assumptions that are difficult to predict. Therefore, our actual results could differ materially and adversely from those expressed in any forward-looking statements as a result of various risk factors.
SOURCE: Unigene Laboratories, Inc.
Investors: The Investor Relations Group Daniel Berg/Dian Griesel, Ph.D. 212-825-3210
UGNE up 9% on Q1 news-
Unigene Announces Strong Increase in Revenue and Improved Quarterly Income for First Quarter 2007
8:00a ET May 11, 2007 (Business Wire)
Unigene Laboratories, Inc. (OTCBB: UGNE) reports its financial results for the quarter ended March 31, 2007.
Revenue for the three months ended March 31, 2007 increased to $6,328,000 compared to $387,000 for the three months ended March 31, 2006. Revenue from Fortical sales and royalties were $4,461,000 for the three months ended March 31, 2007.
Fortical royalties for the three months ended March 31, 2007 increased to $1,845,000 from $198,000 for the three months ended March 31, 2006. First quarter 2007 Fortical royalties include Upsher-Smith sales for the four month period of December 2006 through March 2007. Fortical sales were $2,616,000 for the three months ended March 31, 2007. Sales to Novartis under our supply agreement were $1,408,000 for the three months ended March 31, 2007. There were no product sales for the three months ended March 31, 2006.
Operating income for the three months ended March 31, 2007 increased to $124,000 from an operating loss of $2,856,000 for the three months ended March 31, 2006.
Unigene's net loss for the three months ended March 31, 2007 was $244,000, or $.00 per share, compared to a net loss of $3,243,000, or $.04 per share for the three months ended March 31, 2006.
The three months ended March 31, 2007 and 2006 includes $393,000 and $165,000, respectively, in expenses for non-cash stock option compensation. As of March 31, 2007, Unigene had approximately $697,000 in expenses for non-cash stock option compensation that remains to be recognized, primarily over the next 12 months.
Total operating expenses were $6,204,000 for the three months ended March 31, 2007, an increase from $3,243,000 for the three months ended March 31, 2006. The increase was primarily due to cost of goods sold on product sales to Upsher-Smith and Novartis.
Our cash balance at March 31, 2007 was $4,646,000, an increase of approximately $1,288,000 from December 31, 2006. Accounts receivable at March 31, 2007 were $7,345,000, an increase of $6,105,000 from December 31, 2006. This was primarily a result of the $5,500,000 milestone payment from Novartis which was received in April 2007.
Deferred licensing fees increased $6,169,000 from December 31, 2006, primarily due to the $8,000,000 in payments from Novartis which were only partially recognized as revenue in the first three months of 2007.
Following are recent highlights and developments:
-- According to IMS, prescriptions for Fortical(R), the Company's first U.S. product that was launched in August 2005, grew to 91,000 in March 2007, reflecting a 32% increase from February 2007. The same source reported that prescriptions for the first quarter of 2007 increased 46% as compared to the fourth quarter of 2006. The nasal calcitonin market share for Fortical during that same period grew from 29% to 45%.
-- Subsequent to March 31, 2007, the Company repaid $1 million of outstanding debt and has restructured its loan obligations, recasting $15.7 million in debt as eight-year term loans. The new notes have a fixed simple interest rate of 9%, and no payments are required for the first three years of the notes. This restructuring will reduce the Company's aggregate annual interest payments, replaces all notes that have been in default and will strengthen the Company's financial position.
-- The Company has progressed in its efforts to improve its oral delivery technology and is in the process of filing new patent applications to protect these inventions. These improvements should enhance the Company's oral delivery technology in general and the calcitonin and PTH programs in particular.
"We are very pleased to report the continued growth of Fortical prescriptions," commented Dr. Warren Levy, President and CEO of Unigene. "The significant increase in first quarter revenue will help fuel the Company's activities in new programs. In combination with the partial loan repayment and the restructuring of the Company's debt to eliminate all defaults and lower interest expense, we will significantly improve the Company's balance sheet."
UNIGENE LABORATORIES, INC. CONDENSED BALANCE SHEETS March 31, 2007 December 31, 2006 ----------------- ----------------- ASSETS (Unaudited) Current assets: Cash and cash equivalents $ 4,645,627 $ 3,357,351 Accounts receivable 7,345,442 1,240,114 Inventory 4,554,028 5,283,000 Prepaid expenses and other current assets 281,303 303,444 ----------------- ----------------- Total current assets 16,826,400 10,183,909 Property, plant and equipment, net 2,403,297 2,364,141 Investment in joint venture 30,656 30,545 Patents and other intangibles, net 1,483,009 1,438,848 Other assets 111,389 33,879 ----------------- ----------------- Total assets $ 20,854,751 $ 14,051,322 ================= ================= LIABILITIES AND STOCKHOLDERS' DEFICIT -------------------------------- Current liabilities: Accounts payable $ 928,954 $ 884,958 Accrued expenses - other 1,877,721 1,806,707 Current portion - deferred licensing fees 2,162,756 762,752 Notes payable - stockholders 8,095,000 8,105,000 Accrued interest - stockholders 8,467,004 8,081,180 Current portion - capital lease obligations 65,108 70,780 ----------------- ----------------- Total current liabilities 21,596,543 19,711,377 Deferred licensing fees, excluding current portion 12,925,402 8,156,262 Capital lease obligations, excluding current portion 28,202 40,880 Deferred compensation 340,016 330,643 ----------------- ----------------- Total liabilities 34,890,163 28,239,162 ----------------- ----------------- Commitments and contingencies Stockholders' deficit: Common Stock - par value $.01 per share, authorized 135,000,000 shares, issued and outstanding: 87,734,515 shares in 2007 and 87,731,015 shares in 2006 877,345 877,310 Additional paid-in capital 105,136,739 104,740,178 Accumulated deficit (120,049,496) (119,805,328) ----------------- ----------------- Total stockholders' deficit (14,035,412) (14,187,840) ----------------- ----------------- $ 20,854,751 $ 14,051,322 ================= =================
UNIGENE LABORATORIES, INC. CONDENSED STATEMENTS OF OPERATIONS (Unaudited) Three months ended March 31, 2007 2006 ------------ ----------- Revenue: Product sales $ 4,023,732 $ -- Royalties 1,845,442 197,702 Licensing revenue 230,856 189,189 Development fees and other 228,242 -- -------------- ------------- 6,328,272 386,891 -------------- ------------- Operating expenses: Research, development and facility expenses 2,124,135 1,581,106 Cost of goods sold 2,019,651 -- General and administrative 2,060,235 1,661,877 -------------- ------------- 6,204,021 3,242,983 -------------- ------------- Operating income (loss) 124,251 (2,856,092) Other income (expense): Interest income 31,723 27,024 Interest expense-principally to stockholders (400,142) (413,604) -------------- ------------- Loss before income taxes (244,168) (3,242,672) Income tax expense -- -- -------------- ------------- Net loss $ (244,168) $(3,242,672) ============== ============= Loss per share - basic and diluted: Net loss per share $ (0.00) $ (0.04) -------------- ------------- Weighted average number of shares outstanding - basic and diluted 87,731,376 84,084,903 ============== =============
About Unigene
Unigene Laboratories, Inc. is a biopharmaceutical company focusing on the oral and nasal delivery of large-market peptide drugs. Due to the size of the worldwide osteoporosis market, Unigene is targeting its initial efforts on developing calcitonin and PTH-based therapies. Fortical(R), Unigene's nasal calcitonin product for the treatment of postmenopausal osteoporosis, received FDA approval and was launched in August 2005. Unigene has licensed the U.S. rights for Fortical to Upsher-Smith Laboratories, worldwide rights for its oral PTH technology to GlaxoSmithKline and worldwide rights for its calcitonin manufacturing technology to Novartis. The Company is also manufacturing a second peptide for Novartis. Unigene's patented oral delivery technology has successfully delivered, in preclinical and/or clinical trials, various peptides including calcitonin, PTH and insulin. Unigene's patented manufacturing technology is designed to cost-effectively produce peptides in quantities sufficient to support their worldwide commercialization as oral or nasal therapeutics. For more information about Unigene, call (973) 882-0860 or visit www.unigene.com. For information about Fortical, visit www.fortical.com.
Safe Harbor statements under the Private Securities Litigation Reform Act of 1995: This press release contains forward-looking statements regarding us and our business, financial condition, results of operations and prospects. Such forward-looking statements include those which express plans, anticipation, intent, contingency, goals, targets or future development and/or otherwise are not statements of historical fact. We have based these forward-looking statements on our current expectations and projections about future events and they are subject to risks and uncertainties known and unknown which could cause actual results and developments to differ materially from those expressed or implied in such statements. These forward-looking statements include statements about the following: general economic and business conditions, our financial condition, competition, our dependence on other companies to commercialize, manufacture and sell products using our technologies, the ability of our products to gain market acceptance and increase market share, the uncertainty of results of animal and human testing, the risk of product liability and liability for human trials, our dependence on patents and other proprietary rights, dependence on key management officials, the availability and cost of capital, the availability of qualified personnel, changes in, or the failure to comply with, governmental regulations, the failure to obtain regulatory approvals for our products and other risk factors discussed in our Securities and Exchange Commission filings. Words such as "anticipates," "expects," "intends," "plans," "predicts," "believes," "seeks," "estimates," "may," "will," "should," "would," "potential," "continue," and variations of these words (or negatives of these words) or similar expressions, are intended to identify forward-looking statements. In addition, any statements that refer to expectations, projections, or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to certain risks, uncertainties, and assumptions that are difficult to predict. Therefore, our actual results could differ materially and adversely from those expressed in any forward-looking statements as a result of various risk factors.
SOURCE: Unigene Laboratories, Inc.
Investors: The Investor Relations Group Daniel Berg/Dian Griesel, Ph.D. 212-825-3210
PSUD
PETRO-SUN Inc. (P-S-U-D)
Price Today: .43
How far can it go from here? We are not allowed to speculate!
Check this deal out for yourself.
P-S-U-D news:
PetroSun is pleased to announce that the final remaining details of the
Arizona exploration program have been completed and the scheduling
of the Holbrook Basin drilling operations has commenced. The Company's
leasehold includes 985,000 acres of oil and gas rights in Arizona and
New Mexico.
For the complete release, please see your brokers website
UGNE to release 1st Q results before open tomorrow:
http://www.investorshub.com/boards/read_msg.asp?message_id=19522007
Unigene to Release First Quarter 2007 Results and Host Conference Call on May 11th
8:17a ET May 8, 2007 (Business Wire)
Unigene Laboratories, Inc. (OTCBB: UGNE) will release financial results for the first quarter ended March 31 2007, before the market opens on Friday, May 11th. The Company will also host a conference call that morning, at 9:00 AM EDT to discuss its first quarter financial results and to provide a Company update.
Unigene invites all those interested in hearing management's discussion to join the call by dialing 866-334-3876 for participants in the United States and 416-849-4292 for international participants. A replay will be available for 45 days after the call and can be accessed by dialing 866-245-6755 for participants in the United States and 416-915-1035 for international participants. When prompted, enter passcode #525168. Participants may also access a live webcast of the conference call through the investor relations section of Unigene's website at www.unigene.com. The webcast will be archived on the company's website for 45 days.
About Unigene
Unigene Laboratories, Inc. is a biopharmaceutical company focusing on the oral and nasal delivery of large-market peptide drugs. Due to the size of the worldwide osteoporosis market, Unigene is targeting its initial efforts on developing calcitonin and PTH-based therapies. Fortical(R), Unigene's nasal calcitonin product for the treatment of postmenopausal osteoporosis, received FDA approval and was launched in August 2005. Unigene has licensed the U.S. rights for Fortical to Upsher-Smith Laboratories, worldwide rights for its oral PTH technology to GlaxoSmithKline and worldwide rights for its calcitonin manufacturing technology to Novartis. The Company is also manufacturing a second peptide for Novartis. Unigene's patented oral delivery technology has successfully delivered, in preclinical and/or clinical trials, various peptides including calcitonin, PTH and insulin. Unigene's patented manufacturing technology is designed to cost-effectively produce peptides in quantities sufficient to support their worldwide commercialization as oral or nasal therapeutics. For more information about Unigene, call (973) 882-0860 or visit www.unigene.com. For information about Fortical, visit www.fortical.com.
Safe Harbor statements under the Private Securities Litigation Reform Act of 1995: This press release contains forward-looking statements regarding us and our business, financial condition, results of operations and prospects. Such forward-looking statements include those which express plans, anticipation, intent, contingency, goals, targets or future development and/or otherwise are not statements of historical fact. We have based these forward-looking statements on our current expectations and projections about future events and they are subject to risks and uncertainties known and unknown which could cause actual results and developments to differ materially from those expressed or implied in such statements. These forward-looking statements include statements about the following: general economic and business conditions, our financial condition, competition, our dependence on other companies to commercialize, manufacture and sell products using our technologies, the uncertainty of results of animal and human testing, the risk of product liability and liability for human trials, our dependence on patents and other proprietary rights, dependence on key management officials, the availability and cost of capital, the availability of qualified personnel, changes in, or the failure to comply with, governmental regulations, the failure to obtain regulatory approvals for our products and other risk factors discussed in our Securities and Exchange Commission filings. Words such as "anticipates," "expects," "intends," "plans," "predicts," "believes," "seeks," "estimates," "may," "will," "should," "would," "potential," "continue," and variations of these words (or negatives of these words) or similar expressions, are intended to identify forward-looking statements. In addition, any statements that refer to expectations, projections, or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to certain risks, uncertainties, and assumptions that are difficult to predict. Therefore, our actual results could differ materially and adversely from those expressed in any forward-looking statements as a result of various risk factors.
SOURCE: Unigene Laboratories, Inc.
Unigene Investors: The Investor Relations Group Daniel Berg/Dian Griesel, Ph.D. 212-825-3210 or Media: Janet Vasquez, 212-825-3210
Interesting work with T cells and ca:
Reuters
Updated: 11:32 a.m. ET May 9, 2007
HONG KONG - Scientists in Hong Kong and Australia will soon test an experimental treatment for nose and throat cancer — which “trains” the patient’s own white blood cells to fight the disease.
The trial will begin over the next three months and blood samples will be collected from 30 nasopharyngeal (nose) cancer patients in Hong Kong, said lead researcher Daniel Chua, associate professor of clinical oncology at the University of Hong Kong.
These will be flown to the Queensland Institute of Medical Research, where scientists will isolate and “train” a certain class of white blood cells, or T-cells, to fight the disease.
The battle-ready T-cells will then be cultured and the whole army of cells will be re-injected back into the cancer patients.
Some classes of T-cells have “memory.” Once these T-cells have been exposed to certain invaders and fought them off, they should hopefully launch the same response when they are re-introduced back into the patient’s body.
“(We expect) the T-cells (to) initiate a very aggressive inflammatory reaction and during the process, not only will the T-cells attack the cancer cells, but other immune cells in the body will be called in to eradicate the cancer cells,” Chua told Reuters this week.
Nasopharyngeal cancer, most prevalent in south China, kills one in every three victims and is thought to be linked to diets rich in preserved foods, like salted fish.
Its link to the common Epstein-Barr virus (EBV), from the herpes family of viruses, is well established.
Trained for battle
EBV particles are located inside nasopharyngeal, and T-cells can be trained to recognize EBVs, induce an immune response and kill the cancer cells in the process, Chua said.
The team identified two proteins on EBV particles — LMP1, LMP2 — which T-cells seem to recognize as targets for attack.
“There are different components in virus particles and some are better targets than others; i.e. they can be easily attacked by T-cells if they can be recognized,” Chua said.
“Tumor cells contain the virus particles and when you train the T-cells to attack the virus particles, they actually attack the cancer cells,” Chua explained.
“We will produce the T-cells in large amounts. They should reproduce inside the body and continue to regenerate in the future, so that if the Tumor comes back, they can fight it.”
If the technique works, it could be tried on other cancers with well-established links to viruses, for example, liver cancer, which is linked to hepatitis B virus, Chua said.
I see the proof readers made another mistake,lol.
UGNE presentation today at 4:00.
http://www.investorshub.com/boards/read_msg.asp?message_id=19332771
Phoenix to Triple Its Holdings of Gravel Mining Assets
Tuesday May 8, 9:35 am ET
Company to Acquire a 1,700 Acre Sand and Gravel Mining Operation in Southwest Mississippi; When Combined With Its Pearl River Mining Assets, Phoenix Will Be Largest Supplier of Aggregate Products in the Louisiana and Mississippi Gulf Coast Region
MADISONVILLE, LA--(MARKET WIRE)--May 8, 2007 -- Phoenix Associates Land Syndicate (Phoenix) (Other OTC:PBLS.PK - News) today announced it has entered into an agreement to purchase a 1,700 acre gravel pit in Southwest Mississippi. At current market prices the mineral deposits/reserves of this mine are estimated to be in the one billion to one and a half billion dollars area.
ADVERTISEMENT
Phoenix indicated that adding these reserves to the existing reserves at the 820 acre Murphy Sand & Gravel site in Pearl River, Louisiana, the Company believes it will become the largest supplier of aggregate products on the Gulf Coast of Louisiana and Mississippi.
Paul Alonzo, CEO of Phoenix, stated, "Due to the enormous demand for gravel, different types of sands and soil products, it has made it extremely important for Phoenix to grow this division of our company. Current sales projections for our sand and gravel division exceed our current abilities to deliver product."
Mr. Alonzo added, "As announced in an earlier news release, we are immediately adding another production operation at the Pearl River site. This new pit has three production operations plus classifiers for producing different types of sand that we currently do not have at the Pearl River site, but are in the process of adding at the present time."
The Company expects to close this new acquisition within 90 days. Financing is in place and due diligence has started. Upon closing all financial details will be released to our shareholders and the investment community.
About Phoenix Associates Land Syndicate (PBLS)
Phoenix Associates Land Syndicate (PBLS) is a public holding company, with thousands of stockholders, that has purchased motivated companies in order to enhance its assets and income basis. Since 1978, PBLS has developed assets and/or interests in aviation, sand & gravel, soil products, land development, oil and natural gas, commodity brokering, plumbing, trucking, contract hauling, construction, swimming pool construction and construction related industries. For more information, visit www.pbls.biz.
Forward-Looking Statements
This press release contains statements that are "forward looking" and are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995 and federal securities laws. Generally, the words "expect," "intend," "estimate," "will" and similar expressions identify forward-looking statements. By their very nature, forward-looking statements are subject to known and unknown risks and uncertainties that may cause our actual results, performance or achievements, or that of our industry, to differ materially from those expressed or implied in any of our forward-looking statements. Statements in this press release regarding the Company's business or proposed business, which are not historical facts, are "forward-looking" statements that involve risks and uncertainties, such as estimates and statements that describe the Company's future plans, objectives or goals, including words to the effect that the Company or management expects a stated condition or result to occur. Since forward-looking statements address future events and conditions, by their very nature, they involve inherent risks and uncertainties. Actual results in each case could differ materially from those currently anticipated in such statements. Investors are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date they are made.
Contact:
For More Information Contact:
Mike Mulshine
Osprey Partners
(732) 292-0982
osprey57@optonline.net
--------------------------------------------------------------------------------
Source: Phoenix Associates Land Syndicate
CEL-SCI to Present at BIO 2007 Business Forum
9:00a ET May 7, 2007 (PR NewsWire)
CEL-SCI CORPORATION (Amex: CVM) announced that Geert Kersten, Chief Executive Officer, will be presenting at the BIO 2007 Business Forum, the Biotechnology Industry Organization's Annual International Convention being held at the Boston Convention & Exhibition Center from May 6-9, 2007. Mr. Kersten's presentation will be on Tuesday, May 8th, at 9:15 a.m. local time in Room E.
The BIO Business Forum is the largest partnering and networking program in the industry. It is a program that offers pharmaceutical companies, biotechnology companies, academic research institutions and investors from around the world the unique opportunity to gather in one place at one time to learn about each other and to meet one-on-one to discuss business opportunities of mutual interest.
The Biotechnology Industry Organization (BIO), founded in 1993, is a nonprofit association that represents more than 1,100 biotechnology companies, state and international affiliates, and related organizations. The BIO International Convention offers attendees an opportunity to meet with every key player in the biotechnology industry. Program participants include researchers, academia, entrepreneurs, venture capitalists, and others who will soon be recognized for their vision and achievement. Her Majesty Queen Noor of Jordan and Michael J. Fox are the keynote speakers this year. Additional information about the International Convention and the Business Forum is available at www.bio2007.org.
CEL-SCI Corporation is developing new immune system based treatments for cancer and infectious diseases. The Company has received the go-ahead from the U.S. FDA and the Canadian Regulators to conduct a Phase III clinical trial in advanced primary head and neck cancer patients with its lead product Multikine(R). CEL-SCI's other products, which are currently in pre-clinical stage and have been funded with U.S. government support, have shown protection against a number of diseases in animal tests and are currently being tested against diseases associated with bio-defense and avian flu. The Company has operations in Vienna, Virginia and Baltimore, Maryland.
SOURCE CEL-SCI Corporation
Gavin de Windt of CEL-SCI Corporation, +1-703-506-9460
http://www.cel-sci.com
DSDI new spam/scam
The cream of the crop for 2007 - GET IN EARLY! DSDI IS SET TO ROCK YOUR
PORTFOLIO!
DSI Direct Sales, Inc.
Symbol: DSDI
Price: $0.05
There is a MASSIVE PROMOTION underway this weekend! This is hot, read
the news and get on DSDI first thing Monday!
CHVC spam/scam-
Stop everything you're looking at right now and put your focus here.
Major News Was Released .
CHINA D E A L
China Voice Holding Corp.
C H V C
Here's the News
China Voice Holding Corp. Completes Acquisition of StreamJet Inc. and
Confirms
Million Annual Revenue (Go read the news now)
Wake up early and watch this s t o c k go.
NanoViricides Drugs Found To Be Highly Effective Against Most Recent Strain of the H5N1 Avian Flu Virus
Monday May 7, 7:30 am ET
WEST HAVEN, Conn.--(BUSINESS WIRE)--NanoViricides, Inc. (Pink Sheets: NNVC - News) presented results of recent animal studies against rabies and BSL3 in vitro studies against a Clade 2 H5N1 (avian influenza) virus at the 23rd Annual Symposium of the Pan American Society for Clinical Virology in Tampa, FL, on Wednesday, May 2. (Pan American Society for Clinical Virology (PASCV): Clinical Virology Symposium)
The BSL3 studies against Clade 2 H5N1, a Dec. 2006 isolate in Vietnam, showed that the nanoviricide developed against Highly Pathogenic Influenzas, FluCide-HP (TM), was highly effective in suppressing cytopathic effects (CPE), whereas the broad-spectrum nanoviricide against all influenzas, FluCide(TM), was slightly less effective than AviFluCide-HP. These findings were expected. Both of these candidates were significantly more effective than oseltamivir (Tamiflu®) in this blind study performed by the National Institute of Hygiene and Epidemiology (NIHE) scientists in Vietnam.
In addition, the antibody-fragment-based H5N1 specific (Clade 1, Vietnam, 2004-2005 strains) AviFluCide(TM) drug candidate was demonstrated conclusively by Vietnam scientists to significantly suppress CPE against this rgH5N1 strain (Clade 1), confirming previous results.
The Highly Pathogenic H5N1 subtype of influenza continues to rapidly evolve and is now found in two distinct subgroups, Clade 1 and Clade 2. According to CDC scientists, the Vietnam 2004/2005 strains belong to Clade 1, whereas the Indonesia 2006 (2007), Egypt 2006, and Vietnam 2006 (2007) strains are different and form the Clade 2 subgroup. The various Clade 2 strains are antigenically distinct from each other, but closer to each other than to Clade 1 strains.
"Highly Pathogenic Influenza strains of all clades possess the polybasic cleavage site. Thus FluCide-HP, designed against this site, is expected to be effective against all Highly Pathogenic influenza strains. It makes no difference to which type, subtype, or clade, they belong," said Anil R. Diwan, Ph.D., president of NanoViricides, Inc.
"We have shown that our drug candidates are the most effective drugs at present against even the newest subgroup of H5N1 viruses. Other companies continue to work on developing vaccines and drugs against the older Clade 1 H5N1 viruses, while we are working on the newest strains," said Eugene Seymour, MD, MPH, Chief Executive Officer of NanoViricides, Inc.
The Company plans to comment shortly on its in vitro/in vivo rabies studies.
NanoViricides Drugs Found To Be Highly Effective Against Most Recent Strain of the H5N1 Avian Flu Virus
Monday May 7, 7:30 am ET
WEST HAVEN, Conn.--(BUSINESS WIRE)--NanoViricides, Inc. (Pink Sheets: NNVC - News) presented results of recent animal studies against rabies and BSL3 in vitro studies against a Clade 2 H5N1 (avian influenza) virus at the 23rd Annual Symposium of the Pan American Society for Clinical Virology in Tampa, FL, on Wednesday, May 2. (Pan American Society for Clinical Virology (PASCV): Clinical Virology Symposium)
The BSL3 studies against Clade 2 H5N1, a Dec. 2006 isolate in Vietnam, showed that the nanoviricide developed against Highly Pathogenic Influenzas, FluCide-HP (TM), was highly effective in suppressing cytopathic effects (CPE), whereas the broad-spectrum nanoviricide against all influenzas, FluCide(TM), was slightly less effective than AviFluCide-HP. These findings were expected. Both of these candidates were significantly more effective than oseltamivir (Tamiflu®) in this blind study performed by the National Institute of Hygiene and Epidemiology (NIHE) scientists in Vietnam.
In addition, the antibody-fragment-based H5N1 specific (Clade 1, Vietnam, 2004-2005 strains) AviFluCide(TM) drug candidate was demonstrated conclusively by Vietnam scientists to significantly suppress CPE against this rgH5N1 strain (Clade 1), confirming previous results.
The Highly Pathogenic H5N1 subtype of influenza continues to rapidly evolve and is now found in two distinct subgroups, Clade 1 and Clade 2. According to CDC scientists, the Vietnam 2004/2005 strains belong to Clade 1, whereas the Indonesia 2006 (2007), Egypt 2006, and Vietnam 2006 (2007) strains are different and form the Clade 2 subgroup. The various Clade 2 strains are antigenically distinct from each other, but closer to each other than to Clade 1 strains.
"Highly Pathogenic Influenza strains of all clades possess the polybasic cleavage site. Thus FluCide-HP, designed against this site, is expected to be effective against all Highly Pathogenic influenza strains. It makes no difference to which type, subtype, or clade, they belong," said Anil R. Diwan, Ph.D., president of NanoViricides, Inc.
"We have shown that our drug candidates are the most effective drugs at present against even the newest subgroup of H5N1 viruses. Other companies continue to work on developing vaccines and drugs against the older Clade 1 H5N1 viruses, while we are working on the newest strains," said Eugene Seymour, MD, MPH, Chief Executive Officer of NanoViricides, Inc.
The Company plans to comment shortly on its in vitro/in vivo rabies studies.
Another crook caught-
FROM: Forbes.com
Legal
Raw Sewage
Carrie Coolidge, 03.01.07, 4:40 PM ET
A securities attorney in New York was arrested and charged with engaging in a fraudulent scheme through which he obtained and then illegally sold unregistered restricted securities issued in “PIPEs” (private investments in public equity).
According to a complaint filed by the U.S. attorney for the Southern District of New York, Louis W. Zehil, 41, allegedly sold the unregistered, restricted shares under the false pretense that they were registered and freely tradable, personally reaping illicit profits of more than approximately $17.8 million.
Zehil allegedly directed funds to his personal bank account and also to buy real estate, jewelry, a country club membership and use of an interior decorator for a home he owns.
According to the complaint, Zehil, a corporate attorney, and two entities he controlled, Strong and Chestnut, engaged in a fraudulent scheme to obtain and sell to the investing public millions of shares of securities in violation of the antifraud and registration provisions of the federal securities laws.
Between January 2006 and February 2007, Zehil represented seven public companies in issuing their stock in PIPE transactions. The companies, all of which trade on the over-the-counter bulletin board, were Gran Tierra Energy (otcbb: GTRE - news - people ), Foothills Resources (otcbb: FTRS - news - people ), MMC Energy (otcbb: MMCN - news - people ), Alternative Energy Sources (otcbb: AENS - news - people ), Ethanex Energy (otcbb: EHNX - news - people ), GoFish (otcbb: GOFH - news - people ) and Kreido BioFuels (otcbb: KRBF - news - people ).
In these PIPE transactions, Zehil was able to purchase the restricted stock at a discount to market price.
According to the complaint, Zehil, a New York-based partner with the McGuireWoods law firm until he resigned on Feb. 16, specialized in representing small companies seeking to become public through reverse mergers and obtaining new capital through private placements of stock.
In order to generate financing for the newly merged public company, Zehil assisted these companies in offering securities in transactions near the time of their reverse mergers. In such PIPE transactions, investors commonly commit to purchase a certain number of restricted shares from an issuer at a specified price at a discount to the market price (or expected market price after the reverse merger). In turn, the issuer agrees to file a resale registration statement at a later date so that the investors can sell their shares in the public market.
According to the complaint, however, in this case the securities owned by Zehil were not yet registered with the Securities and Exchange Commission (SEC).
Zehil personally invested in each of the companies through two entities, Chestnut Capital Partners II and Strong Branch Ventures IV, both Delaware limited partnerships. According to the complaint, Chestnut and Strong are both located at Zehil's Ponte Vedra Beach, Fla., home. Chestnut has only two shareholders: Zehil and his wife, the complaints says, while Strong's only general partner was Zehil and its only limited partner was his wife.
As counsel for the issuers of the unregistered securities, Zehil sent opinion letters to the issuers' stock transfer agents directing that all of the issued shares should bear restrictive legends except the shares issued to Chestnut Capital Partners II and Strong Branch Ventures.
Zehil's letters falsely claimed that the shares issued to Strong and Chestnut satisfied legal criteria permitting them to be issued without a restrictive legend. As a result, Zehil was able to receive shares without restrictive legends and, almost immediately thereafter, he sold them in the public market at a profit in advance of the other PIPE investors. In all cases, he did this before the issuers had filed registration statements with the SEC.
Interestingly, it was not the SEC or the U.S. attorney's office that uncovered the alleged wrongdoing. Credit goes to an associate attorney at McGuireWoods who reported it to the firm's management. McGuireWoods management then confronted Zehil, who admitted to three of the firm's partners that he intentionally issued false opinions to the transfer agents exempting Strong and Chestnut from the restrictive legend requirement.
Zehil had circumvented the firm's policy, which requires all opinion letters be reviewed by at least one other partner. McGuireWoods then brought the alleged wrongdoing to the attention of the SEC and is now cooperating with the government investigations.
In addition to the illicit profits, Zehil also received nearly 1.5 million shares of GoFish and 1.4 million shares of Kreido, which remain unsold.
If convicted, Zehil faces a maximum sentence of 20 years in prison and a fine that would be the largest of $5 million, twice the gross gain from the offense, or twice the gross loss to the victims.
Andrew M. Lawler, a New York-based white-collar criminal defense attorney who is representing Zehil, declined to comment
Biophan has the technology and it is criminal for implantable device cos not to use it!
--------------------------------------------------------------------------------
Technology Helps Women with Implanted Devices be Screened for Breast Cancer with MRI Scans
PITTSFORD, N.Y., May 7 /PRNewswire-FirstCall/ -- Magnetic resonance
imaging (MRI) is already well-established as a premier non-invasive imaging
technology, and now women can count on MRIs for early detection of breast
cancer.
However, according to Biophan Technologies' CEO Michael Weiner, women
with implantable pacemakers, defibrillators, and other medical devices may
not have cause to rejoice just yet -- patients with many implantable
devices still cannot undergo MRIs.
Earlier this year, the New England Journal of Medicine published a
study that focused on the function and effectiveness of MRI in the
detection of breast cancer. MRIs use magnetic fields to highlight and
differentiate between normal and abnormal tissue.
In nearly 1,000 women diagnosed with breast cancer in one breast, a MRI
scan was able to detect breast cancer in the other breast in 3 percent (30
out of 969) women. The presence of these abnormal tissues was missed by
both mammography and clinical examination.
However, patients with breast cancer who also have implanted devices
cannot be exposed to MRI, says Weiner, whose company specializes in
technology for making implantable devices safe and visible under MRI
imaging.
According to Weiner, the trouble lies with the implanted leads, which
contain metal wires that connect the devices to tissue, as well as other
metallic devices that act as antennas and absorb energy from the MRI
machine.
This can cause the tissue near the lead to heat up as well as generate
voltages that can cause potentially fatal arrhythmias (irregular heart
beat), rapid heartbeats in heart tissue, and other problems in the brain
and nervous system.
The patented technologies developed by Biophan can be built into leads
and devices to reduce heating and induced voltages to safe levels.
Recognizing that different devices have varying design requirements, the
company has developed a wide range of innovative solutions designed for
various types of implants.
In addition, the company has also developed methods for making devices,
such as stents, visible under MRI, to non-invasively detect in-stent
restenosis and clotting. At the present time, this diagnosis requires
invasive procedures such as an angiogram or intravascular ultrasound.
Enhancing public awareness of the technological "disconnect" between
medical devices and MRI safety is part of Biophan's mission. The team has
contributed to improved methods for measuring heating and induced voltages
in many commonly used medical devices.
"Creating the technology that will help make implantable devices safe
for MRI is more critical than ever," Weiner says. "As the diagnostic
capability of MRI continues to advance, and as the availability of MRI
machines increases worldwide, so should the availability of implantable
devices that are MRI-safe."
For more information, go to http://www.biophan.com.
Same old scammer back again:
Promoting sym: UTEV
Current: $0.008
1 Day Target price: $.06
Action: Strong buy!!
500%+ profit (short term)..
"VROS",lol,lol. They cant even get their email address correct,lol.
"We only have about 10 posters here its not exactly a busy board, does it not seem odd to you that 3 more join IHUB for the first time within 24 hours of each other at a weekend. All posting positivly about NWOG one claiming to have insider information and russian."
Sure does does'nt it and I have marked every one of them just in case!
lol,lol.
Could terrorist scum be behind some of the stocks posted here?
May 3, 2007
HP-386
2007 National Money Laundering Strategy Released
The U.S. Departments of Treasury, Justice, and Homeland Security today joined together in issuing the 2007 National Money Laundering Strategy, a report detailing continued efforts to dismantle money laundering and terrorist financing networks and bring these criminals to justice.
"The 2007 National Money Laundering Strategy is a direct result of close cooperation by the Departments of Justice, Treasury and Homeland Security, along with our foreign counterparts, and signifies our collective commitment to fight money laundering," said Assistant Attorney General Alice S. Fisher of the Justice Department's Criminal Division. "Implementation of this strategy will greatly assist in efforts to seize and forfeit millions in illegal proceeds that flow through the international financial system."
The 2007 Strategy addresses the priority threats and vulnerabilities identified by the Money Laundering Threat Assessment released in 2006, the product of an extremely valuable investigation into the current and emerging trends and techniques used by criminals to raise, move, and launder proceeds. The Assessment – the first government-wide analysis of its kind – brought together the expertise of regulatory, law enforcement, and investigative officials from across the government, culminating in a comprehensive analysis of specific money laundering methods, patterns of abuse, geographical concentrations, and the associated legal and regulatory regimes.
"The 2007 National Money Laundering Strategy builds upon the groundbreaking work of the Money Laundering Threat Assessment," said Pat O'Brien, Treasury's Assistant Secretary for Terrorist Financing. "Focusing on well-established money laundering methods and emerging trends identified in the Assessment, we have created a robust strategy for combating money laundering, deterring criminals, and addressing areas vulnerable to exploitation."
The 2007 Strategy builds on initiatives and programs pioneered in preceding National Money Laundering Strategies. The constant searching by criminals for new ways to launder and hide dirty money is evidence of our successful regulatory and law enforcement efforts to safeguard the banking system. With an aim at continuing these robust efforts, the 2007 Strategy places an emphasis on bolstering the efficiency of the anti-money laundering processes currently in place.
"In every type of case, from human smuggling and drug trafficking to intellectual property rights violations and illegal alien employment schemes, the need to hide and move ill-gotten gains is a constant. ICE's anti-money laundering initiatives are at the forefront of attacking existing and emerging money laundering threats" said Julie L. Myers, Assistant Secretary for Immigration and Customs Enforcement at the Department of Homeland Security. "ICE's trade transparency unit, bulk cash smuggling initiative and programs targeting illegal money service businesses and stored value card schemes are making it less profitable to commit these crimes."
Additionally, the 2007 Strategy focuses on leveling the playing field internationally, helping to ensure U.S. financial institutions are not disadvantaged through the implementation of controls and standards to combat money laundering and terrorist financing. Indeed, money laundering is a global threat the United States is working to address through international bodies, including the Financial Action Task Force (FATF), and through direct private sector outreach in regions around the world.
REPORTS
Speaking of "crazed believers" whatever happened to our most famous NNVC buyer Microcrappe Matthead?
Remember, dont let crooks scam you!
Junior Gold c Company TRDX set to Soar!
In today's markets gold is King and there is no better
place to make Significant Money than Junior gold c companies.
Do a search on "junior gold coompany" and you will see that
they are Making a killing and so are the people who Follow
them.
TRDX is just such a company and is practically in IPO
stage. It was recently featured in USA Today and MAJOR
results from the field are expected any day.
This coupled with a Hot Promotion are sending this one
straight Up!
Trend Exploration Inc.
Currrent Price: $0.49 / Targget Price: $2.00
Get in early this time. You won't be disappointed!
Energy Watch : 05 May 2007
Posted : Sat, 05 May 2007 03:25:59GMT
Author : Energy Analysis Editor
Category : Energy (Environment)
News Alerts by Email click here )
Energy Environment News | Home
By ANDREA R. MIHAILESCU Gazprom presses Exxon to sell Sakhalin-1 stakeRussian gas giant Gazprom is looking to secure an agreement with participants of Russia's Far East Sakhalin-1 project to purchase all of the produced gas and to obtain exclusive rights for its export.
Alexander Medvedev, deputy CEO of Gazprom, said Gazprom was holding consultations with the operator company of Sakhalin-1. Gazprom representatives say they want to manage all gas produced in the framework of the project frequently. According to analysts, when Gazprom wants to obtain something with such persistence, it will definitely receive this. Participants of the Sakhalin-1 project are project-operator Exxon Neftegaz Ltd. with 30 percent; Japan's SODECO with 30 percent; India's ONGC with 20 percent; and Rosneft with 20 percent.
The Sakhalin-1 project includes development of Chaivo, Odoptu and Arkutun-Dagi on the northeastern seabed of Sakhalin. Potential recoverable reserves of these fields amount to abut 307 million tons of oil and 485 billion cubic meters of gas.Russian oil firm to develop oil, gas in LibyaRussia's North West Oil Group said it plans to start developing oil and gas fields in Libya in cooperation with one of Russia's leading state-owned energy companies. The oil group's president, Ernest Malyshev, held talks Thursday with officials from the Libyan government to discuss developing a field in the country, North West Oil Group said in a statement.
The only Russian companies that currently hold licenses to develop fields in Libya are Gazprom and Tatneft.The two companies received licenses to explore the Libyan oil and gas shelf as part of a tender at the end of 2006. Tatneft won three of the fourteen licenses that were sold, while Gazprom received one. Gazprom received a tender for a license to develop oil and gas block 19 on Libya's sea shelf, according to an Interfax report.North-West Oil Group, formerly Nord Oil International, was established in St. Petersburg in 2004. It sells oil and gas, produces and sells petroleum products and petrochemical products, and is a publicly traded Oil & Gas company trading under the ticker symbol NWOG on the U.S. Pink sheets market. Norway invests $6M for oil management in Madagascar Norway said it has agreed to invest approximately $6 million for the management of the oil and gas sector in Madagascar. The agreement was signed by Norwegian Ambassador Hans Frederik Lehne and Madagascan Minister of Economy, Finance and Budget Andriamparany Radavidson Benjamin. The project involves developing oil policies and strategies, the revising and developing legal and fiscal cadre, mastering of resource evaluation, intensive training of personnel as well as the elaborating and organizing programs on oil promotion.
The Madagascan government wants to begin producing oil from its promising offshore oilfields, and the first production of oil is expected by the end of this year. Ten companies have been working on Madagascan oil sector for years. Closing oil prices, May 4, 3 p.m. LondonBrent crude oil: $66.97West Texas Intermediate crude oil: $64.03(e-mail: AMihailescu@upi.com)
http://www.earthtimes.org/articles/show/59551.html
http://spamnation.info/stocks/
".5 Are stock spams sent by the company concerned?
It's hard to say, but it seems that in many cases the answer is 'no'.
It's easy to assume that a spam which appears to promote a company must have been sent by that company. However, other individuals or organizations also have an interest in promoting a stock. These include third-party speculators who hold shares in that stock, brokers and market makers who buy and sell the stock, and marketing firms who have been paid to advertise it.
Stock spam can lead to short-term increases in a company's share price, but these are usually followed by a sharp fall. This can be very damaging to the company. This is one reason why it's not usually in the interests of the company to send stock spam.
In contrast, dishonest speculators can often gain by talking up the price of a stock. Some recent studies, including a study by Rainer Böhme and Thorsten Holz, and another study by Laura Frieder and Jonathan Zittrain have shown that this kind of stock manipulation can be highly profitable.
It seems likely that most current stock spam is sent by third-party speculators."
Good post doc-thanks.
Did I see scam alert in that translation,lol?
DER INVESTORALARM! OJU.F BEGINNT HOCHGEHEN! DONNERSTAG 3. MAG STARTET
DIE HAUSSE!
Company: ORAMED PHARMA
WKN : A0J3FG
ISIN : US68403P1049
Markt: Frankfurt
Kurzel : OJU.F
Letztr Kurs: 0.477
4 Tages Prognose: 2.15
ES IST EIN UNGLAUBLICHES PROFITPOTENTIAL! VERLIERE DIESE CHANCE NICHT!
The PR of May 1st was not an official PR??
"you guys are really grasping now."
Grasping,lol? Even if SLJB is legit, who in the financial world would take the company seriously with a PR like that????
FAIRFIELD, N.J.--(BUSINESS WIRE)--Unigene Laboratories, Inc.'s (OTCBB: UGNE - News) President and CEO, Dr. Warren Levy, will speak at the UBS Global Generic and Specialty Pharmaceuticals Conference on Tuesday, May 8, 2007 at 4:00 PM. Dr. Levy will present information on Unigene's products and collaborations to analysts, portfolio managers, investment bankers and other financial professionals. The conference will be held at The Grand Hyatt in New York City from May 8-9, 2007.
ADVERTISEMENT
A live audio webcast of the presentation will also be available on the UBS website at www.ibb.ubs.com under the conference tab. An audio replay of the presentation will begin three hours after the presentation time and will be available until June 8, 2007.
MERCK, NOVARTIS PRODUCTS
Bone-building drugs may damage heart
Posted by the Asbury Park Press on 05/3/07
THE ASSOCIATED PRESS
BOSTON — Two research reports suggest a possible link between two bone-building drugs and irregular heart rhythms in a small number of women who take the medicine.
The signs of a problem were more pronounced with Reclast, a drug made by Novartis AG and given through a once-a-year, 15-minute intravenous infusion. But there was a hint of similar trouble in a few women who took the leading osteoporosis pill, Fosamax by Merck & Co., which is based in Readington, N.J. The two drugs are in the same class.
The safety question caught researchers by surprise. While uncertain how big a worry it might be, they agreed the overall risk is small. Specialists said women at high risk for bone breaks — the main target of these osteoporosis drugs — should keep taking them as prescribed.
But several experts said they'd be cautious about those who also are at risk for a condition called atrial fibrillation, an irregular heart rhythm that can cause strokes.
The two separate reports published Thursday in The New England Journal of Medicine point to elevated rates of serious episodes of that heart condition in women who took Reclast and Fosamax.
Doctors made available by Merck and Novartis said the problem could be a statistical fluke or just a product of aging. They said earlier studies showed no sign of the possible risk.
For now, it's unknown if the possible risk applies to other drugs in the class known as biphosphonates. Future studies are expected to help clarify the risk.
Take adventage
Adrenaline Nation Entertainment, Inc.
_A_D N_N_
Major News was released today:
_A_D_N N_
Adrenaline Nation Television Signs Affiliate Licensing Agreement
With Global eNetwork to Provide eCommerce Solutions Through the iTV
MediaPlex With TelvOS Operating System Powered by Narrowstep
Keith Dressel is starting his next venture so it's time to pay
attention now.
Keith was a record executive responsible for over $4 billion in
record sales. He personally helped generate 29 gold records, 26
platinum albums, and 85 gold singles.
What he's doing now is so hot, so huge, it will blow your mind! Go
read the news and go check out the website. This new program is
incredible!
_____
Information within this report contains forward looking statements
within the meaning of Section 27A of the Securities Act of 1933 and
Section 21B of the SEC Act of 1934. Statements that involve
discussions with respect to projections of future events are not
statements of historical fact and may be forward looking
statements. Don't rely on them to make a decision. Past performance
is never indicative of future results. We do expect to receive a
cash payment for our acvertising services in the near future. The
amount is unknown at this time. Un-affiliated Third parties may own
stock and will sell those shares without notice to you. This report
shall not be construed as any kind of investment advice or
solicitation
BCRX up .66 on favorable avian flu animal studies.
http://www.investorshub.com/boards/read_msg.asp?message_id=19312974
BioCryst to Release First Quarter 2007 Financial Results on Wednesday, May 9, 2007
7:45a ET May 2, 2007 (PR NewsWire)
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced its first quarter 2007 financial results will be released on Wednesday, May 9, 2007. At 10:00 a.m. Eastern Time, BioCryst will host a conference call and live webcast. The call will be led by Jon P. Stonehouse, Chief Executive Officer, and Michael A. Darwin, Chief Financial Officer. BioCryst management will discuss the company's first quarter results and provide an update on the company's other programs and business results.
To access the webcast via the internet, log on to http://www.biocryst.com. Please connect to the website at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be needed to hear the webcast. Alternately, please call 1-866-293-8970 (U.S.) or 1-913-312-1230 (international). Telephone replay will be available. To access the replay, please call 1-888-203-1112 (U.S.) or 1-719-457-0820 (international) and dial the participant passcode 9133874. The webcast will be archived on http://www.biocryst.com.
About BioCryst
BioCryst Pharmaceuticals, Inc. is a leader in the use of crystallography and structure-based drug design for the development of novel therapeutics to treat cancer, cardiovascular diseases, autoimmune diseases, and viral infections. The company is advancing multiple internal programs toward potential commercialization including Fodosine(TM) in oncology, BCX-4208 in transplantation and autoimmune diseases and peramivir in seasonal and life- threatening influenza. BioCryst has a worldwide partnership with Roche for the development and commercialization of BCX-4208, and is collaborating with Mundipharma for the development and commercialization of Fodosine(TM) in markets across Europe, Asia, Australia and certain neighboring countries. In January, 2007 the U.S. Department of Health and Human Services (DHHS) awarded a $102.6 million, four-year contract to BioCryst for advanced development of peramivir to treat seasonal and life-threatening influenza. In February, 2007 BioCryst established a partnership with Shionogi & Co., to develop and commercialize peramivir in Japan. For more information about BioCryst, please visit the company's web site at http://www.biocryst.com.
Forward-looking statements
This press release contains forward-looking statements, including statements regarding future results, performance or achievements. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Some of the factors that could affect the forward-looking statements contained herein include that the favorable results of peramivir in animals may not be replicated in humans, that development and commercialization of Fodosine(TM) in both T-ALL and CTCL may not be successful, that we may not resolve satisfactorily the particulate matter issue with the intravenous formulation of Fodosine(TM), that we may not obtain a satisfactory SPA for Fodosine(TM) for treatment of CTCL promptly or at all, that DHHS could reduce or eliminate funding for peramivir, that we or our licensees may not be able to enroll the required number of subjects in planned clinical trials of our product candidates and that such clinical trials may not be successfully completed, that BioCryst or its licensees may not commence as expected additional human clinical trials with our product candidates, that our product candidates may not receive required regulatory clearances from the FDA, that ongoing and future clinical trials may not have positive results, that we may not be able to complete successfully the Phase IIb trial for Fodosine(TM) that is currently planned to be pivotal, that we or our licensees may not be able to continue future development of our current and future development programs, that our development programs may never result in future product, license or royalty payments being received by BioCryst, that BioCryst may not reach favorable agreements with potential pharmaceutical and biotech partners for further development of its product candidates, that BioCryst may not have sufficient cash to continue funding the development, manufacturing, marketing or distribution of its products and that additional funding, if necessary, may not be available at all or on terms acceptable to BioCryst. Please refer to the documents BioCryst files periodically with the Securities and Exchange Commission, specifically BioCryst's most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, current reports on Form 8-K which identify important factors that could cause the actual results to differ materially from those contained in the projections or forward-looking statements.
Contact: BioCryst Pharmaceuticals, Inc. Jonathan M. Nugent V.P. Corporate Communications (205) 444-4633
SOURCE BioCryst Pharmaceuticals, Inc.
Jonathan M. Nugent, V.P. Corporate Communications of BioCryst Pharmaceuticals, Inc., +1-205-444-4633
http://www.biocryst.com
BioCryst to Release First Quarter 2007 Financial Results on Wednesday, May 9, 2007
7:45a ET May 2, 2007 (PR NewsWire)
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced its first quarter 2007 financial results will be released on Wednesday, May 9, 2007. At 10:00 a.m. Eastern Time, BioCryst will host a conference call and live webcast. The call will be led by Jon P. Stonehouse, Chief Executive Officer, and Michael A. Darwin, Chief Financial Officer. BioCryst management will discuss the company's first quarter results and provide an update on the company's other programs and business results.
To access the webcast via the internet, log on to http://www.biocryst.com. Please connect to the website at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be needed to hear the webcast. Alternately, please call 1-866-293-8970 (U.S.) or 1-913-312-1230 (international). Telephone replay will be available. To access the replay, please call 1-888-203-1112 (U.S.) or 1-719-457-0820 (international) and dial the participant passcode 9133874. The webcast will be archived on http://www.biocryst.com.
About BioCryst
BioCryst Pharmaceuticals, Inc. is a leader in the use of crystallography and structure-based drug design for the development of novel therapeutics to treat cancer, cardiovascular diseases, autoimmune diseases, and viral infections. The company is advancing multiple internal programs toward potential commercialization including Fodosine(TM) in oncology, BCX-4208 in transplantation and autoimmune diseases and peramivir in seasonal and life- threatening influenza. BioCryst has a worldwide partnership with Roche for the development and commercialization of BCX-4208, and is collaborating with Mundipharma for the development and commercialization of Fodosine(TM) in markets across Europe, Asia, Australia and certain neighboring countries. In January, 2007 the U.S. Department of Health and Human Services (DHHS) awarded a $102.6 million, four-year contract to BioCryst for advanced development of peramivir to treat seasonal and life-threatening influenza. In February, 2007 BioCryst established a partnership with Shionogi & Co., to develop and commercialize peramivir in Japan. For more information about BioCryst, please visit the company's web site at http://www.biocryst.com.
Forward-looking statements
This press release contains forward-looking statements, including statements regarding future results, performance or achievements. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Some of the factors that could affect the forward-looking statements contained herein include that the favorable results of peramivir in animals may not be replicated in humans, that development and commercialization of Fodosine(TM) in both T-ALL and CTCL may not be successful, that we may not resolve satisfactorily the particulate matter issue with the intravenous formulation of Fodosine(TM), that we may not obtain a satisfactory SPA for Fodosine(TM) for treatment of CTCL promptly or at all, that DHHS could reduce or eliminate funding for peramivir, that we or our licensees may not be able to enroll the required number of subjects in planned clinical trials of our product candidates and that such clinical trials may not be successfully completed, that BioCryst or its licensees may not commence as expected additional human clinical trials with our product candidates, that our product candidates may not receive required regulatory clearances from the FDA, that ongoing and future clinical trials may not have positive results, that we may not be able to complete successfully the Phase IIb trial for Fodosine(TM) that is currently planned to be pivotal, that we or our licensees may not be able to continue future development of our current and future development programs, that our development programs may never result in future product, license or royalty payments being received by BioCryst, that BioCryst may not reach favorable agreements with potential pharmaceutical and biotech partners for further development of its product candidates, that BioCryst may not have sufficient cash to continue funding the development, manufacturing, marketing or distribution of its products and that additional funding, if necessary, may not be available at all or on terms acceptable to BioCryst. Please refer to the documents BioCryst files periodically with the Securities and Exchange Commission, specifically BioCryst's most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, current reports on Form 8-K which identify important factors that could cause the actual results to differ materially from those contained in the projections or forward-looking statements.
Contact: BioCryst Pharmaceuticals, Inc. Jonathan M. Nugent V.P. Corporate Communications (205) 444-4633
SOURCE BioCryst Pharmaceuticals, Inc.
Jonathan M. Nugent, V.P. Corporate Communications of BioCryst Pharmaceuticals, Inc., +1-205-444-4633
http://www.biocryst.com
St. Jude Study Shows Effectiveness of Peramivir in Prevention of Mortality in Mouse Model of Avian Influenza H5N1 Virus Infection
7:30a ET May 2, 2007 (PR NewsWire)
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that investigators at St. Jude Children's Research Hospital, Memphis, TN, reported favorable results evaluating peramivir treatment in an animal model of influenza using a highly virulent strain of H5N1 virus (an avian influenza strain that had caused fatal human infection in Viet Nam). The study, presented on April 30, 2007 by Dr. David Boltz at the 20th International Conference on Antiviral Research, Palm Springs, CA, concluded that peramivir is an effective treatment when administered intramuscularly to control H5N1 infection in mice and that these data support the potential use of this drug to control influenza in the event of a pandemic.
The objective of the study was to achieve complete protection against lethal H5N1 influenza virus infection in the mouse model through the use of intramuscular administration of peramivir, a potent neuraminidase inhibitor with antiviral activity against strains of influenza viruses, including seasonal strains and influenza H5N1 strains from avian origins.
A survival rate of 40% to 60% was observed in mice treated with one or two injections of peramivir; however, 100% survival of mice was achieved by two injections of peramivir on the first day followed by once-daily administration for 7 days. The longer duration of peramivir treatment also prevented viral replication in the tissues of the lungs, brain and spleen of the mice at the 3, 6, and 9 day post-inoculation time points.
W. James Alexander, MD, MPH, BioCryst Senior Vice President for Clinical Operations commented, "The results of this St. Jude study, performed under the careful guidance of Drs. Elena Govorkova and Robert Webster, bolsters our confidence that peramivir may be clearly beneficial in the treatment of severe influenza, including human influenza due to strains of avian origin. We wish to congratulate our colleagues at St. Jude on the successful conduct of an elegant study which not only confirms but significantly extends the observations of the previous animal study reported last year by NIH showing positive effects of peramivir in a similar model of H5N1 influenza virus infection."
BioCryst is advancing the clinical development of peramivir under terms of a contract from the U.S. Department of Health and Human Services (DHHS) which on January 4, 2007 awarded BioCryst a $102.6 million, four-year contract to develop peramivir for the treatment of seasonal and life-threatening influenza. Funding from the contract will support manufacturing of clinical lots, process validation, clinical studies and other product approval requirements needed for U.S. licensure. BioCryst retains 100% development and commercialization rights to peramivir worldwide other than in Japan and Korea where BioCryst recently established strategic partnerships with Shionogi & CO. in Japan, and Green Cross in Korea.
About Peramivir
Peramivir is a member of the class of antiviral agents that inhibit influenza viral neuraminidase, an enzyme that is essential for the spread of influenza virus within the host. Peramivir is an inhibitor of influenza A and B neuraminidases and certain strains of influenza viruses that may be resistant to available neuraminidase inhibitors are susceptible to peramivir in laboratory tests. At the 46th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy in September, 2006, data were presented showing that injectable formulations of peramivir were safely administered to healthy subjects at daily doses up to approximately 600 mg. At the same meeting, animal data were presented showing peramivir promoted survival in animals infected with highly pathogenic strains of the H5N1 virus. Peramivir injection has received Fast Track designation from US FDA and the availability of an intravenous neuraminidase inhibitor may be important in treating patients hospitalized with severe and potentially life-threatening influenza. The availability of an intramuscular formulation of peramivir could ensure appropriate dosing which may be a concern with currently available oral or inhaled anti-influenza agents.
About Influenza
The influenza virus causes an acute viral disease of the respiratory tract. Unlike the common cold and some other respiratory infections, seasonal flu can cause severe illness, resulting in life-threatening complications. According to the Centers for Disease Control and Prevention, every year in the United States more than 200,000 people are hospitalized from flu complications, and about 36,000 people die from flu. Most at risk are young children, the elderly, and people with seriously compromised immune systems.
Avian influenza A viruses of H5N1 subtype are circulating among birds worldwide, the virus is considered extremely contagious in fowl. It is believed that all species of birds are susceptible to avian influenza, but domestic poultry, including chickens and turkeys, are among the more susceptible to the highly pathogenic strain. According to the World Health Organization, at least 261 people have contracted H5N1 avian influenza, of which at least 157 have died. Almost all of these infections are believed to have resulted from contact with infected poultry.
About BioCryst
BioCryst Pharmaceuticals, Inc. is a leader in the use of crystallography and structure-based drug design for the development of novel therapeutics to treat cancer, cardiovascular diseases, autoimmune diseases, and viral infections. The company is advancing multiple internal programs toward potential commercialization including Fodosine(TM) in oncology, BCX-4208 in transplantation and autoimmune diseases and peramivir in seasonal and life- threatening influenza. BioCryst has a worldwide partnership with Roche for the development and commercialization of BCX-4208, and is collaborating with Mundipharma for the development and commercialization of Fodosine(TM) in markets across Europe, Asia, Australia and certain neighboring countries. In January, 2007 the U.S. Department of Health and Human Services (DHHS) awarded a $102.6 million, four-year contract to BioCryst for advanced development of peramivir to treat seasonal and life-threatening influenza. In February, 2007 BioCryst established a partnership with Shionogi & Co., to develop and commercialize peramivir in Japan. For more information about BioCryst, please visit the company's web site at http://www.biocryst.com.
Forward-looking statements
This press release contains forward-looking statements, including statements regarding future results, performance or achievements. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Some of the factors that could affect the forward-looking statements contained herein include that the favorable results of peramivir in animals may not be replicated in humans, that development and commercialization of Fodosine(TM) in both T-ALL and CTCL may not be successful, that we may not resolve satisfactorily the particulate matter issue with the intravenous formulation of Fodosine(TM), that we may not obtain a satisfactory SPA for Fodosine(TM) for treatment of CTCL promptly or at all, that DHHS could reduce or eliminate funding for peramivir, that we or our licensees may not be able to enroll the required number of subjects in planned clinical trials of our product candidates and that such clinical trials may not be successfully completed, that BioCryst or its licensees may not commence as expected additional human clinical trials with our product candidates, that our product candidates may not receive required regulatory clearances from the FDA, that ongoing and future clinical trials may not have positive results, that we may not be able to complete successfully the Phase IIb trial for Fodosine(TM) that is currently planned to be pivotal, that we or our licensees may not be able to continue future development of our current and future development programs, that our development programs may never result in future product, license or royalty payments being received by BioCryst, that BioCryst may not reach favorable agreements with potential pharmaceutical and biotech partners for further development of its product candidates, that BioCryst may not have sufficient cash to continue funding the development, manufacturing, marketing or distribution of its products and that additional funding, if necessary, may not be available at all or on terms acceptable to BioCryst. Please refer to the documents BioCryst files periodically with the Securities and Exchange Commission, specifically BioCryst's most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, current reports on Form 8-K which identify important factors that could cause the actual results to differ materially from those contained in the projections or forward-looking statements.
Contact: BioCryst Pharmaceuticals, Inc. Jonathan M. Nugent V.P. Corporate Communications (205) 444-4633
SOURCE BioCryst Pharmaceuticals, Inc.
Jonathan M. Nugent, V.P. Corporate Communications of BioCryst Pharmaceuticals, Inc., +1-205-444-4633
http://www.biocryst.com